S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: In vivo antitumor effects

被引：0

作者：

Iguchi, Motofumi ^{[1
]}

Tanaka, Hidekazu ^{[1
]}

Wada, Tohru ^{[1
]}

Hojo, Kanji ^{[1
]}

Shinonome, Satomi ^{[1
]}

Sato, Norihito ^{[1
]}

Nezasa, Ken-ichi ^{[1
]}

Orita, Satoshi ^{[1
]}

Abe, Kenji ^{[1
]}

Arimura, Akinori ^{[1
]}

Matsuo, Yoshiyuki ^{[1
]}

Kato, Akira ^{[1
]}

机构：

[1] Shionogi & Co Ltd, Osaka, Japan

来源：

CANCER RESEARCH | 2009年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1762

引用

页数：1

共 50 条

[41] 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.
Beckers, TL
Reissmann, T
Schmidt, M
Fiebig, H
Burger, AM
Pongratz, H
Husky, H
Mahboobi, S
[J]. CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3808S - 3808S
[42] A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity
Gowan, SM
Harrison, JR
Patterson, L
Valenti, M
Read, MA
Neidle, S
Kelland, LR
[J]. MOLECULAR PHARMACOLOGY, 2002, 61 (05) : 1154 - 1162
[43] NVP-AUY922:: A novel small molecule HSP90 inhibitor with potent in vivo antitumor efficacy
Jensen, Michael Rugaard
Schoepfer, Joseph
Radimersky, Thomas
Massey, Andrew
Brueggen, Josef
Schweitzer, Alain
Pfaar, Ulrike
Ruetz, Stephan
Guy, Chantal
Buckler, Alan
Schnell, Christian
Cozens, Robert
Brough, Paul
Drysdale, Martin
Quadt, Cornelia
Garcia-Echeverria, Carlos
Chene, Patrick
[J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3521S - 3521S
[44] Discovery of a Potent, Selective, and Orally Available MTHFD2 Inhibitor (DS18561882) with in Vivo Antitumor Activity
Kawai, Junya
Toki, Tadashi
Ota, Masahiro
Inoue, Hidekazu
Takata, Yoshimi
Asahi, Takashi
Suzuki, Makoto
Shimada, Takashi
Ono, Kaori
Suzuki, Kanae
Takaishi, Sachiko
Ohki, Hitoshi
Matsui, Satoshi
Tsutsumi, Shinji
Hirota, Yasuhide
Nakayama, Kiyoshi
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (22) : 10204 - 10220
[45] Design and synthesis of small-molecule radiotracer prototypes for imaging EGFR and HER2 using PET and SPECT
Corcoran, Emily B.
Hanson, Robert N.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
[46] In vivo characterization of AMG 900, an orally active small molecule inhibitor of aurora kinases in phase 1 clinical trials
Bush, Tammy L.
Ziegler, Beth
Chung, Grace
McElroy, Patricia L.
Kendall, Richard
Radinsky, Robert
Geuns-Meyer, Stephanie
Payton, Marc
[J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[47] The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
Nagasaka, Misako
Singh, Vijendra
Baca, Yasmine
Sukari, Ammar
Kim, Chul
Mamdani, Hirva
Spira, Alexander, I
Uprety, Dipesh
Bepler, Gerold
Kim, Edward S.
Raez, Luis E.
Pai, Sachin Gopalkrishna
Ikpeazu, Chukwuemeka
Oberley, Matthew
Feldman, Rebecca
Xiu, Joanne
Korn, W. Michael
Wozniak, Antoinette J.
Borghaei, Hossein
Liu, Stephen, V
[J]. CLINICAL LUNG CANCER, 2022, 23 (01) : 52 - 59
[48] Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC
Neal, J.
Doebele, R.
Riely, G.
Spira, A.
Horn, L.
Piotrowska, Z.
Costa, D.
Zhang, S.
Bottino, D.
Zhu, J.
Kerstein, D.
Li, S.
Janne, P.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S599 - S599
[49] Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo
Meco, Daniela
Servidei, Tiziana
Riccardi, Anna
Ferlini, Cristiano
Cusano, Gabriella
Zannoni, Gian Franco
Giangaspero, Felice
Riccardi, Riccardo
[J]. NEURO-ONCOLOGY, 2009, 11 (03) : 250 - 259
[50] CUDC-101, a synthetic and potent HDAC, EGFR and Her2 inhibitor, effectively inhibits proliferation of cancer cell lines
Lai, Cheng
[J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3519S - 3519S

← 1 2 3 4 5 →